Independent PML::RARA-positive acute promyelocytic leukemia arising during BCR::ABL1-positive chronic myeloid leukemia.

IF 1.4
Takanori Yoshioka, Akira Kondo, Masayuki Matsuda, Yasuhisa Sando, Makoto Nakamura, Nobuharu Fujii, Kazutaka Sunami
{"title":"Independent PML::RARA-positive acute promyelocytic leukemia arising during BCR::ABL1-positive chronic myeloid leukemia.","authors":"Takanori Yoshioka, Akira Kondo, Masayuki Matsuda, Yasuhisa Sando, Makoto Nakamura, Nobuharu Fujii, Kazutaka Sunami","doi":"10.3960/jslrt.26010","DOIUrl":null,"url":null,"abstract":"<p><p>Acute promyelocytic leukemia (APL) arising during the clinical course of BCR::ABL1-positive chronic myeloid leukemia (CML) is rare and may represent either promyelocytic blast phase or the emergence of an independent Philadelphia chromosome-negative clone. We report an octogenarian man with chronic-phase CML who was intolerant to multiple tyrosine kinase inhibitors and underwent temporary discontinuation of asciminib. During molecular relapse, bone marrow examination revealed 88% abnormal promyelocytes with Auer rods and markedly elevated PML::RARA transcripts, whereas BCR::ABL1 transcript levels were more than 3 logs lower than at CML diagnosis. Conventional cytogenetics demonstrated t(15;17) without t(9;22) as the dominant clone, supporting de novo APL arising independently of the residual CML clone. All-trans retinoic acid plus arsenic trioxide achieved molecular remission of PML::RARA and was followed by an initial marked reduction in BCR::ABL1 transcript levels, which subsequently remained detectable at low levels during continued follow-up. This case highlights the importance of integrated cytogenetic and molecular evaluation to distinguish blast phase from independent leukemogenesis in patients with CML who develop cytopenias.</p>","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"66 2","pages":"142-147"},"PeriodicalIF":1.4000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13472210/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical and experimental hematopathology : JCEH","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3960/jslrt.26010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Acute promyelocytic leukemia (APL) arising during the clinical course of BCR::ABL1-positive chronic myeloid leukemia (CML) is rare and may represent either promyelocytic blast phase or the emergence of an independent Philadelphia chromosome-negative clone. We report an octogenarian man with chronic-phase CML who was intolerant to multiple tyrosine kinase inhibitors and underwent temporary discontinuation of asciminib. During molecular relapse, bone marrow examination revealed 88% abnormal promyelocytes with Auer rods and markedly elevated PML::RARA transcripts, whereas BCR::ABL1 transcript levels were more than 3 logs lower than at CML diagnosis. Conventional cytogenetics demonstrated t(15;17) without t(9;22) as the dominant clone, supporting de novo APL arising independently of the residual CML clone. All-trans retinoic acid plus arsenic trioxide achieved molecular remission of PML::RARA and was followed by an initial marked reduction in BCR::ABL1 transcript levels, which subsequently remained detectable at low levels during continued follow-up. This case highlights the importance of integrated cytogenetic and molecular evaluation to distinguish blast phase from independent leukemogenesis in patients with CML who develop cytopenias.

独立PML:: rara阳性急性早幼粒细胞白血病发生在BCR:: abl1阳性慢性粒细胞白血病。
急性早幼粒细胞白血病(APL)在BCR:: abl1阳性慢性髓性白血病(CML)的临床过程中出现是罕见的,可能代表早幼粒细胞母细胞期或独立的费城染色体阴性克隆的出现。我们报告了一位八十多岁的慢性慢性粒细胞白血病患者,他对多种酪氨酸激酶抑制剂不耐受,暂时停用阿西米尼。在分子复发期间,骨髓检查显示88%的早幼粒细胞出现Auer棒异常,PML::RARA转录物显著升高,而BCR::ABL1转录物水平比CML诊断时低3倍以上。常规细胞遗传学证明t(15;17)不含t(9;22)为优势克隆,支持新生APL独立于残余CML克隆产生。全反式维甲酸加三氧化二砷实现了PML::RARA的分子缓解,随后BCR::ABL1转录物水平最初显着降低,随后在继续随访期间仍可检测到低水平。本病例强调了综合细胞遗传学和分子评估的重要性,以区分细胞减少的CML患者的母细胞期和独立的白血病发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书